ASCO GU 2024: Darolutamide + ADT + docetaxel effective, well-tolerated SoC for mHSPC

14 Jun 2024
ASCO GU 2024: Darolutamide + ADT + docetaxel effective, well-tolerated SoC for mHSPC
ARASENS post hoc sensitivity analysis data presented at ASCO GU 2024 support primary OS analysis and demonstrate that darolutamide + ADT + docetaxel is an effective, well-tolerated SoC for mHSPC. 
The above content is for medical education purpose supported by Bayer HealthCare Limited.

Related MIMS Drugs

Resources

ASCO GU 2024: Darolutamide + ADT + docetaxel effective, well-tolerated SoC for mHSPC

ASCO GU 2024: Darolutamide + ADT + docetaxel effective, well-tolerated SoC for mHSPC

ASCO GU 2024: Darolutamide + ADT + docetaxel effective, well-tolerated SoC for mHSPC

ASCO GU 2024: Darolutamide + ADT + docetaxel effective, well-tolerated SoC for mHSPC